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Background: Anaemia, in particular due to iron deficiency, is common in pregnancy with associated negative
outcomes for mother and infant. However, there is evidence of significant variation in management. The objectives
of this review of systematic reviews were to analyse and summarise the evidence base, identify gaps in the
evidence and develop a research agenda for this important component of maternity care.
Methods: Multiple databases were searched, including MEDLINE, EMBASE and The Cochrane Library. All systematic
reviews relating to interventions to prevent and treat anaemia in the antenatal and postnatal period were eligible.
Two reviewers independently assessed data inclusion, extraction and quality of methodology.
Results: 27 reviews were included, all reporting on the prevention and treatment of anaemia in the antenatal
(n = 24) and postnatal periods (n = 3). Using AMSTAR as the assessment tool for methodological quality, only 12 of
the 27 were rated as high quality reviews. The greatest number of reviews covered antenatal nutritional
supplementation for the prevention of anaemia (n = 19). Iron supplementation was the most extensively researched,
but with ongoing uncertainty about optimal dose and regimen. Few identified reviews addressed anaemia
management post-partum or correlations between laboratory and clinical outcomes, and no reviews reported on
clinical symptoms of anaemia.
Conclusions: The review highlights evidence gaps including the management of anaemia in the postnatal period,
screening for anaemia, and optimal interventions for treatment. Research priorities include developing standardised
approaches to reporting of laboratory outcomes, and information on clinical outcomes relevant to the experiences
of pregnant women.Background
Anaemia is the most common disorder of pregnancy
with estimates of global prevalence reaching over 40%
[1]. Iron deficiency is the commonest cause of anaemia
but other causes include nutritional deficiencies, bone
marrow suppression and haemolytic or hereditary dis-
eases. Blood loss during, as well as shortly after, birth
may further contribute to postpartum anaemia.
The consequences of anaemia in pregnancy are poten-
tially far-reaching, both for mother and infant. Several
studies have identified anaemia as a risk factor for* Correspondence: jacquismail@gmail.com
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reproduction in any medium, provided the orintrauterine fetal death, premature birth, low birth weight
and other adverse neonatal outcomes [2,3]. Some suggest
a link between maternal anaemia in pregnancy and later
developmental problems in children [4,5]. Postpartum
maternal anaemia may be associated with breathlessness,
lethargy, infection, lactation failure and depression [2,5-7].
Despite this, there is evidence of significant variation in
practice and sub-optimal management of maternal an-
aemia [8-10], possibly due to a lack of consistent, detailed
information derived from good quality evidence.
We carried out a review of systematic reviews to sum-
marise the evidence base, to identify gaps in the evidence
and to develop a research agenda for this important com-
ponent of maternity care. The primary focus of this re-
view was the range of interventions used to prevent andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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The project focussed on systematic reviews of rando-
mised controlled trials (RCTs) as the most robust form of
study design to address the effectiveness of interventions.
Given the expected clinical diversity in practices and
populations, we choose not to include reviews that fo-
cussed on resource poor countries. This review of sys-




A comprehensive search was performed in December
2009, and updated on 11 May 2011, using the biblio-
graphic databases: MEDLINE (1950 onwards), EMBASE
(1980 onwards), The Cochrane Library Issue 5, 2011,
CINAHL (1982 onwards), British Nursing Index (1994
onwards), MIDIRS: Maternity and Infant Care, UKBTS
SRI Transfusion Evidence Library, BMJ Clinical Evidence
and Open SIGLE (System for Grey Literature in Eur-
ope). The review authors also checked the reference
lists of all identified trials, relevant review articles and
current treatment guidelines for further literature.
Details of the search strategies are provided in Add-
itional file 1. Searches were not restricted by language
or publication date.
Inclusion/Exclusion criteria
All systematic reviews of interventions to prevent and
treat anaemia in women, of any ethnicity or age group,
during the maternity period (conception to 1 year post-
partum), were eligible for inclusion. Systematic reviews
from resource poor countries that were not considered
relevant to health care systems in developed countries,
and reviews focussing exclusively on women with inher-
ited disorders of haemoglobin synthesis, e.g. thalassae-
mia and sickle-cell disease, were excluded as these were
not the intended focus of our review. Systematic reviews
focussing on the intrapartum period (onset of labour to
completion of third stage) were also excluded as such
reviews are primarily concerned with specialised obstet-
ric interventions to reduce blood loss rather than the
management of anaemia per se.
All interventions and outcomes relevant to prevention
and treatment of maternal anaemia in pregnancy and
the postpartum, were considered. Outcome measures
did not form part of the eligibility criteria for inclusion.
To be included as a systematic review, the study had to
use a systematic search attempting to identify all studies
meeting their eligibility criteria.
Data collection and analysis
One reviewer screened all titles/abstracts for relevance
and excluded citations were checked by a secondreviewer. Only irrelevant titles/abstracts were excluded
at this stage (e.g. techniques for pelvic surgery in subfer-
tility). The remaining studies were assessed for inclusion
on the basis of their full text, using the criteria indicated
above. Data inclusion, extraction and quality of method-
ology were independently assessed by two reviewers and
any disagreements resolved by consensus with a third
experienced reviewer with subject specific expertise.
Included studies were initially mapped onto a table
(Table 1) demonstrating the area of anaemia manage-
ment (i.e. prevention or treatment) and divided into the
following categories - antenatal: from conception to the
onset of labour; postnatal: from completion of the third
stage to 1 year postpartum. This table was used to iden-
tify areas that have been extensively researched and
those with lack of data (evidence gaps). Analysis
included a narrative synthesis, presented in tabulated
and text form, of all included studies. Conclusions were
based on patterns of results across reviews.Assessment of methodological quality
Appraisal of the quality of the systematic reviews was
determined using AMSTAR; a measurement tool to as-
sess the methodological quality of systematic reviews
[12] (Appendix 2, see Additional file 2). The tool con-
sists of 11 items, in the form of questions, about the
methodological quality of each systematic review. The
11 items were assessed for each review and the total
number of positive answers for each was documented.
The reviews were then divided into the following cat-
egories - high quality: 9 or more positive answers; inter-
mediate quality: 5–8 positive answers; low quality: 4 or
less positive answers. This provided an overall rating of
each systematic review that could be used in the inter-
pretation of the narrative results.Results
Search results
The search identified 1,378 records of which the majority
(n = 1,123) were eliminated by title/abstract (see Figure 1).
255 records were reviewed as full text articles, with 163
excluded because they were not a systematic review or
did not fulfil the inclusion criteria. A further 65 were
excluded as they focussed on the intrapartum period.
The remaining 27 reviews formed the basis of the ana-
lysis (Appendix 3 shows complete list of references, see
Additional file 3). Reviews were first mapped according
to the time period (antenatal or postnatal) and area of
anaemia management (prevention or treatment) that
was the predominant focus of each review (Table 1). The
total numbers in each section differ slightly from those
in Figure 1 as some systematic reviews mapped to more
than one section.
Table 1 Mapping of included systematic reviews
Interventions around prevention and screening Interventions around treatment
Antenatal Nutrition supplementation Total=19 Nutrition supplementation Total=3
Multiple/ micronutrients Fishman, S (2000)* Iron &/or folate Mathews, F (1996)
Villar, J (2003) Rasmussen, K (2001)*
Haider, B (2006) " Reveiz, L (2007)* "
Haider, B (2011) "
Vitamin A Faisel, H (2000)
Van den Broek, N (2002) "
Vitamin E Rumbold, A (2005) "
Vitamin C Rumbold, A (2005) "
Iron & folic acid only Gulmezoglu, M (1997)
Kulier, R (1998)





Reveiz, L (2007)* "
Peña-Rosas, J (2009) "
Macedo, A (2010)
Yakoob, M (2011) "
Organisation of antenatal care Total=5
Scholl, T (1994)
Carroli, G &Villar, J (2001) "
Villar, J (2001) "
Carroli, G &Rooney, C (2001)
Dodd, J (2007) "
Postnatal (up to 1 year) Iron Total=1 Iron &/or erythropoietin Total=3
Fishman, S (2000)* Dodd, J (2004) "
Kotto-Kome, A (2004)
AHRQ (2006)*
* Systematic review included in more than one row/column.
" Systematic review categorised as high quality.
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and postnatal period
All identified systematic reviews reported on the preven-
tion and treatment of anaemia in the antenatal (n = 24)
and postnatal period (n = 3). There was some crossover
between the antenatal and postnatal period in two of the
systematic reviews. All were published between 1994
and 2011, with the majority (n = 21) being published
from 2000 to 2011 (see Additional file 4: Table S2). Only
three reviews exclusively included RCTs from the devel-
oped world [13-15]. The largest number covered ante-
natal nutritional supplementation for the prevention of
anaemia (n = 19), including the use of iron and folic acid.
Five reviews addressed the role of antenatal care organ-
isation in preventing anaemia. Only a small number of
reviews reported on interventions for the treatment of
antenatal anaemia (n = 3) and for the prevention (n = 1)
and treatment (n = 3) of postnatal anaemia.
Assessment of methodological quality
Three of the 27 systematic reviews reported data for all
AMSTAR items (Table 2). The most common items that
no data was reported for were item 5 (providing a list of
studies, both included and excluded) and item 10 (theassessment of publication bias). Unavailable data was
reported as CA, and nine reviews had this response at
least once. As a result of the AMSTAR assessment, 12
systematic reviews were categorised as high quality, four
as intermediate quality and 11 as low quality systematic
reviews. Of the 12 high quality reviews, 11 focussed pre-
dominantly on antenatal prevention of anaemia (8 on
nutritional supplementation, 3 on organisation of ante-
natal care). Only one high quality review focussed pre-
dominantly on the postnatal period, and this was for the
treatment of anaemia rather than its prevention.
Through the text we have indicated the quality of the
review alongside its findings/recommendations in order
to allow the reader to consider the findings/recommen-
dation in light of the review’s measured quality.
The antenatal period: prevention of anaemia
Use of iron and/or folate (n = 12 reviews)
Laboratory outcomes Twelve systematic reviews
addressed the role of iron and/or folate in the prevention
of anaemia [17,24-34]. These reviews included RCTs
with diverse settings and included women known to be
anaemic or iron deficient as well as non-anaemic
1378 hits 
255
1123 eliminated by title/abstract: 
• 388 - incorrect population 
• 377 - incorrect intervention 
• 253 - incorrect population & intervention 
• 56   - not a systematic review 
• 49   - duplicates & withdrawn papers 
All papers found 
228 papers excluded: 
• 65 – intraprtum period 
• 93 - not a systematic review 
• 29 - anaemia/blood loss not studied 
• 9   - incorrect population 
• 5   - incorrect intervention 
• 12 - no intervention (prevalence data) 






* 1 paper contains some postnatal data 
** 1 paper contains some antenatal data 
Figure 1 Flow diagram. A diagram mapping out the number of records identified, included and excluded, during the review process and the
reasons for exclusions.
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tion increased haematological markers (haemoglobin or
haematocrit), improved serum ferritin levels, and
decreased the incidence of anaemia. Three reviews
[27,32,33] (one high, one intermediate and one low qual-
ity) showed that such positive effects extended into the
postnatal period, with improved maternal haemoglobin
concentrations one month to eight weeks postpartum.
One systematic review of high quality [32] and one
of low quality, [27] reported infant outcomes. In both,
infants born to iron supplemented mothers had a
higher serum ferritin at birth compared to non-
supplemented women. Pena-Rosas 2009 [32] found the
effect to be maintained for up to six months (MD 0.09
95% CI 0.05–0.13).
No systematic reviews provided definitive evidence on
the optimum dose or regimen of iron administration.Studies assessed different doses of ferrous iron (daily
dose 27–200 mg), duration of therapy and gestational
age at which treatment commenced. Two high quality
reviews [32,34] reported that the risk of anaemia at
term was similar for supplementation with daily or
intermittent iron alone, compared with iron and folic
acid. One review, of low quality, Sloan 2002 [29]
showed a positive dose response between iron supple-
mentation and maternal haemoglobin concentrations,
however no conclusion could be drawn in regard to op-
timal duration of therapy as higher doses of iron were
used in studies with shorter therapy periods, thus con-
founding the results. Villar 2003 [17] reported on daily
versus weekly or twice weekly supplementation with
both iron and folic acid. This review included one RCT
which demonstrated that daily supplementation resulted
in significantly higher increases in haemoglobin, two
Table 2 Appraisal of methodological quality
Paper AMSTAR Question No. of Y Overall Quality
1 2 3 4 5 6 7 8 9 10 11
Fishman, S (2000) [16] Y N N N N Y N N NA N N 2 Low
Villar, J (2003) [17] Y CA Y CA Y Y Y N Y N N 6 Intermediate
Haider, B (2006) [18] Y Y Y Y Y Y Y Y Y Y Y 11 High "
Haider, B (2011) [19] Y Y Y Y Y Y Y Y Y N Y 10 High "
Faisel, H (2000) [20] Y N Y Y N N N N NA N N 3 Low
Van den Broek, N (2002) [21] Y Y Y Y Y Y Y Y Y N Y 10 High "
Rumbold, 2005 (Vit E) [22] Y Y Y Y Y Y Y Y Y N Y 10 High "
Rumbold, 2005 (Vit C) [23] Y Y Y Y Y Y Y Y Y N Y 10 High "
Gulmezoglu, M (1997) [24] Y CA Y CA N Y Y Y NA N Y 6 Intermediate
Kulier, R (1998) [25] Y N Y CA N Y Y Y Y N N 6 Intermediate
De Onis, M (1998) [26] CA CA N CA N Y Y Y Y N N 4 Low
Milman, N (1999) [27] N N N N N Y N N NA N N 1 Low
Rasmussen, K (2001) [28] Y N N N N Y Y Y NA N N 4 Low
Sloan, N (2002) [29] Y CA N N N N N N Y N Y 3 Low
AHRQ, 2006 [30] Y N Y CA N N Y Y NA N N 4 Low
Reveiz, L (2007) [31] Y Y Y Y Y Y Y Y Y N Y 10 High "
Pena-Rosas, J (2009) [32] Y Y Y Y Y Y Y Y Y Y Y 11 High "
Macedo, A (2010) [33] Y CA Y Y N Y Y Y NA N Y 7 Intermediate
Yakoob, M (2011) [34] Y Y Y Y Y Y Y Y Y N Y 10 High "
Scholl, T (1994) [13] CA N N N N Y N N CA N Y 2 Low
Carroli G &Villar J ( 2001) [35] Y Y Y Y N Y Y Y Y Y Y 10 High "
Villar, J (2001) [36] Y Y Y Y Y Y Y Y Y Y Y 11 High "
Carroli G &Rooney C (2001) [37] Y N Y Y N N N N NA N N 3 Low
Dodd, J (2007) [38] Y Y Y Y Y* Y* Y* Y* Y* CA Y 10 High "
Mathews, F (1996) [39] Y N Y N N N Y Y NA N N 4 Low
Dodd, J (2004) [14] Y Y Y Y Y Y Y Y Y N Y 10 High "
Kotto-Kome, A (2004) [15] Y N N N N Y N N Y N N 3 Low
* Review did not include any studies therefore decision based on methodology.
Y = Yes.
N = No.
NA = Not applicable.
CA = Cannot answer.
Quality categories:.
Low = 4 or less Y answers.
Intermediate = 5–8 Y answers.
High " = 9 or more Y answers.
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of four trials which concluded that daily supplements of
iron and folic acid were superior to weekly. However
this meta-analysis included trials with significant het-
erogeneity and the review was only assessed to be of
intermediate quality.
Clinical outcomes including adverse effects
We identified little information relating to clinical out-
comes. Pena-Rosas 2009 [32] (a high quality review)
found no significant difference in small for gestational
age, birthweight, perinatal death, or admission to special
care unit, among infants whose mothers received ironand folic acid supplementation or not. Data from three
RCTs suggested that women receiving iron supplemen-
tation had a lower risk of receiving blood transfusion
(RR 0.61; 95% CI 0.38–0.96). Macedo 2010 [33] (an
intermediate quality review) identified two RCTs that
showed improved birthweight in iron supplemented
women, and one RCT that showed a reduction in pre-
term labour and perinatal mortality. Nevertheless het-
erogeneity between RCTs led the authors to conclude
that no definitive link between iron supplementation
and improvement in pregnancy outcomes could be
made. One low quality systematic review [28] reported
that the supplementation of non-anaemic women with
Parker et al. BMC Pregnancy and Childbirth 2012, 12:56 Page 6 of 10
http://www.biomedcentral.com/1471-2393/12/56iron and/or folic acid did not affect birth weight or dur-
ation of pregnancy.
Few systematic reviews reported on adverse events
associated with the prevention of anaemia. Three
reviews [29,32,33] (one high, one intermediate and one
low quality) concluded that adverse events, primarily
gastrointestinal (nausea and epigastric pain), were more
common with iron than placebo, and with higher versus
lower doses of iron supplementation.
Use of different supplements (n = 7 reviews)
Laboratory outcomes
Seven systematic reviews (four of high quality) investi-
gated the effects of micronutrients other than iron and
folic acid [16,18-23] and found no evidence to support
the use of vitamin B12, vitamin C, calcium or zinc to
prevent anaemia during pregnancy. Vitamin C is
reported to enhance absorption of non-haem iron and
mobilisation of iron, but the reviews highlighted uncer-
tainty in the optimal role and schedule for Vitamin C
supplementation on outcomes such as maternal anaemia
or other measures of iron status [23].
Four of the seven systematic reviews assessed the role
of vitamin A [16,17,20,21], although only one was of
high quality. [21] All included a single RCT (Suharno
1993 [40]) which demonstrated higher mean haemoglo-
bin concentrations and lower prevalence of anaemia at
birth for women who had received a combination of
vitamin A and iron, compared to women who received
vitamin A or iron alone. However, these findings were
not supported by the other included RCTs. The dose
and duration of vitamin A supplementation varied
from 2,400–60,000 μg/day, and between 6–28 weeks. It
was not clear at what gestational age supplementation
was started. In one low quality review [16] riboflavin was
reported to enhance the haematological response to iron
supplementation (5–9 mg of riboflavin for 6 weeks). The
role of multivitamins compared to iron and folic acid
supplementation was less clear [16,18,19].
Clinical outcomes
Haider 2011 [19] (a high quality review) concluded that
the use of multivitamins significantly reduced the inci-
dence of small for gestational age infants when com-
pared to iron and folate supplementation alone
(RR = 0.91 95% CI 0.86–0.96). No other review reported
any clinical outcomes for mother or infant.
Organisation of antenatal care (n = 5 reviews)
Five systematic reviews focussed on the organisation of
antenatal services [13,35-38], and three of the five were
of high quality. One, Dodd 2007 [38] (a high quality re-
view) compared maternal and infant outcomes for
women with multiple pregnancies managed in dedicatedversus routine antenatal clinics but did not identify any
relevant RCTs. Three systematic reviews [35-37] (two of
which are high quality) addressed the number and fre-
quency of antenatal care visits; all included a single RCT
that incorporated maternal anaemia as an outcome.
There was no difference in risk of maternal anaemia at
term between standard and reduced visit antenatal care.
A fifth, Scholl 1994 [13] (a low quality review) identified
two RCTs that found no difference in risk of anaemia
between dedicated antenatal care programmes for ado-
lescents (including social support, schooling support,
more intensive health promotion and education) and
standard antenatal care.The antenatal period: treatment of anaemia
Use of iron (n = 3 reviews)
Laboratory outcomes We identified one systematic re-
view [31] (high quality) which included information on
the use of iron and laboratory outcomes in the treatment
of anaemia in the antenatal period. Overall treatment
with iron, regardless of dose, method of administration,
or frequency, consistently increased levels of maternal
haemoglobin, haematocrit and serum ferritin, measured
at different times during pregnancy. In general, daily
iron supplementation was found to be more effective
than weekly or twice weekly regimes, at increasing the
mean haemoglobin. Parenteral iron preparations (intra-
muscular and intravenous) when compared to oral iron,
were reported to improve haematological markers and
reduce the incidence of anaemia at term. No difference
was found in the number of women who attained
haemoglobin greater than 11 g/dl, when comparing the
combination of intravenous iron sucrose with recombin-
ant human erythropoietin.Clinical outcomes
We identified three systematic reviews examining the
use of iron and clinical outcomes in the treatment
of anaemia in the antenatal period. Reveiz 2007 [31],
the only high quality systematic review in this area,
found no evidence that increases in haematological
markers led to any clinical improvements for mother
or infant. However, very few of the RCTs assessed
clinical outcomes and those that did were not suffi-
ciently powered to detect any clinical effect. Rasmus-
sen 2001 [28] (low quality) assessed the effect of
antenatal iron and folic acid supplementation of an-
aemic women on birth weight and gestational age of
infants and reported no statistically significant differ-
ence. The gestational age at which treatment com-
menced varied and was often not specified. Iron
dosage and preparation also varied and ranged from
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be considered too low for clinical effect. The review
by Mathews 1996 [39] (low quality) only included
one RCT that evaluated routine iron supplementation
versus targeted supplementation and found that mean
gestational age and infant length at birth were
greater in the routine supplement group but not sta-
tistically significant. There was no difference in mean
birth weight or placental weight. No details of the
dose regime were provided.
The incidence of gastrointestinal side effects was more
common with oral iron (n = 244 RR 0.33 95% CI 0.15–
0.74) [31]. Trials that compared daily with weekly or
twice weekly regimes did not identify any benefit with
regards to side effects other than constipation. Severe
adverse events were more common with parenteral iron
therapies [31]. Use of intravenous iron dextran was asso-
ciated with higher risk of severe allergic reactions, but
the authors were unable to establish the level of risk.
Comparative studies of different formulations of intra-
venous iron were generally lacking, precluding more ac-
curate assessments of risk of adverse reactions. A
possible increased risk of venous thrombosis was noted
in one review; one RCT suggested that this risk could be
reduced by adding hydrocortisone (n = 30 RR 0.09 95%
CI 0.01–1.51) [31].Use of different supplements
No reviews relating to laboratory or clinical outcomes
with the use of micronutrients other than iron, in the
treatment of anaemia during pregnancy, were
identified.The postnatal period: prevention of anaemia (n = 1)
Laboratory outcomes
We identified one systematic review [16] (low quality)
that looked at the effects of nutritional interventions to
prevent anaemia in the postpartum. In a socially
deprived population, multivitamins combined with folic
acid administered from the second trimester to birth sig-
nificantly increased the mean haemoglobin and haem-
atocrit at six weeks postpartum, compared to
multivitamins alone. In one trial, addition of 5 mg ribo-
flavin to iron supplementation administered for six
weeks postpartum augmented plasma levels of iron and
ferritin when compared to iron alone.Clinical outcomes
No reviews reported clinical outcomes for the use of
iron or micronutrients in the prevention of postpartum
anaemia.The postnatal period: treatment of anaemia (n = 3)
Laboratory outcomes
Two systematic reviews (one high quality [14] and one
low quality [15]) addressed the role of erythropoietin in
combination with iron supplementation in tackling ma-
ternal anaemia in the first six weeks postpartum. They
included nine RCTs, conducted in developed countries.
Doses of erythropoietin ranged from 150–300 units/kg
and frequency of administration varied from a single
dose to a daily course over 15 days. Iron dosage ranged
from 160–400 mg per day, with two trials randomising
women to either intravenous or oral iron. The reviewers
concluded that the combination of erythropoietin and
iron raised haemoglobin more quickly than oral iron
alone, but that by day 14 of administration the difference
had disappeared.
Clinical outcomes
Three systematic reviews addressed clinical outcomes in
the treatment of maternal anaemia postpartum
[14,15,30], yet only one was of high quality [14]. Two
reviews [14,15] showed that women receiving erythropoi-
etin were more likely to be lactating on discharge (two
RCTs), with a decrease in postnatal depression scores in
the erythropoietin treatment arm. No adverse events
were recorded. The erythropoietin group demonstrated a
significant increase in platelet count, but no increased
thrombotic events. The AHRQ review [30] included a
trial of iron supplementation versus placebo in mothers
with iron deficiency anaemia. Infants of anaemic mothers
had delays in their development, particularly in hand-to-
eye coordination, and mothers were less engaged and re-
sponsive towards their babies. Supplementation was
started at six to eight weeks postpartum, but the dose
and duration of supplementation was unclear.
Discussion
The main objective of this review was to identify gaps in
the evidence for the prevention and treatment of mater-
nal anaemia in pregnancy and up to 1 year postpartum,
and to inform the research agenda. This topic remains a
concern to health care professionals and public health
specialists, as well as to women themselves, but the lit-
erature addressing this field is widely dispersed over a
number of specialist publications/fields and has not been
previously systematically collated.
One of the first striking gaps in the evidence base is in
the management of maternal anaemia up to one year
postpartum (Table 1). Secondly, across all identified sys-
tematic reviews, 25 included interventions for the pre-
vention of anaemia, compared with only six reviews that
included interventions for the treatment of anaemia.
Thirdly, none of the reviews reported on the best meth-
ods of screening for anaemia. Finally, the majority of
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plementation, including the use of iron which was con-
sistently shown to improve haematological parameters
and decrease the risk of anaemia at term. It was, how-
ever, impossible to make definitive statements about
optimum dose or regimen, due to the heterogeneity be-
tween trials.
There was limited evidence to demonstrate that ribo-
flavin, folic acid, vitamin A and the use of erythropoietin
could enhance a response to iron. It is, therefore, unclear
how or whether these other supplements should be used
in current practice. No reviews examined the use of diet-
ary modification or food support for the management of
anaemia, and no reviews reported on cost-effectiveness
of different approaches.
No reviews reported on clinical symptoms of anaemia
and few reported on the correlation between laboratory
and clinical outcomes. Despite evidence of improvement
in haematological parameters with use of iron there was
limited evidence to indicate that the reduction in ante-
natal maternal anaemia had any clinical impact for
mother or infant, other than reducing the need for blood
transfusion. There was some evidence to suggest that
prompt treatment of postnatal anaemia may be benefi-
cial in preventing postnatal depression and improving
lactation, infant development and maternal bonding but
the quality of this review was poor therefore results
should be interpreted with caution. Data on adverse
effects such as maternal exhaustion were lacking from
the systematic review literature. A number of reviews
reported on the use of different antenatal care programs
for the prevention of antenatal anaemia, but there was
no evidence that any type of program, including fre-
quency of visits, was superior.
Recommendations do exist for best practice regarding
the investigation and management of anaemia but these
guidelines also seem to reflect many of the evidence un-
certainties highlighted in this overview. The National In-
stitute for Clinical Excellence (NICE) provides guidance
on the management of antenatal care [41] and postnatal
care [42], but in the postnatal guidelines there is no
mention of the word ‘anaemia’. The RCOG green-top
guideline for blood transfusion in obstetrics [43] high-
lights the importance of screening and treating anaemia,
with oral or parental iron, in order to reduce the
chances of later blood transfusion. Yet within these
guidelines it is indicated that these are only ‘good prac-
tice points’ indicating that high-quality, systematically
derived evidence is lacking.
Methodological quality of the included systematic
reviews was variable with less than half assessed as being
of high quality, thus consequently many of these system-
atic reviews are of limited utility for those seeking an
evidence base to practice. 11 of the 12 high qualityreviews fell across prevention of anaemia in the ante-
natal period and thus the findings and recommendations
for practice from these reviews would be deemed to be
more robust. Only one review of high quality was found
for the postnatal period. Further systematic reviews in
the postnatal period should meet the criteria for quality
appraisal (PRISMA [44]) and provide information both
on existing systematic reviews and the novel contribu-
tion of the new review.
A limitation of this review is the variation in practices
and populations within and between countries, which
may impact on the generaliseability of findings, although
we partially addressed this by excluding reviews focus-
sing on resource poor countries. A limitation of the
methods used for this review of reviews is that, inevit-
ably, there may be some recently published trials that
have not yet been included in systematic reviews and
thus are not included in our review. There is also some
overlap in analyses of the same primary RCTs between
systematic reviews; we have clearly identified where this
has occurred.
The findings from this review of reviews have implica-
tions for new primary research and the research agenda.
Anaemia management remains an uncertain area of re-
search focus, despite its clinical importance. The identi-
fication or management of maternal anaemia was the
main stated aim in only seven reviews [14-
16,27,28,33,34] and overall, the number of RCTs that
specifically reported on outcomes relevant to maternal
anaemia was small (median 7, interquartile range 1–23).
A further priority is to develop standardised
approaches to the reporting of laboratory outcomes as
the heterogeneity of populations and settings, drug
dosages and regimens and definitions of anaemia pre-
cluded quantitative analysis for many reviews. Outcomes
relevant to the experiences and wellbeing of pregnant
women and new mothers need to be included in future
randomised controlled trials. Additional work is needed
to identify the most effective way of managing anaemia
in the postnatal period; validating an effective screening
policy for both the ante and postnatal periods; and
developing consensus on best practice for the treatment
of maternal anaemia, including the dose, route and regi-
mens of drugs including specifically iron. The role of
universal supplementation strategies for iron has been
evaluated in low-income postpartum women and needs
wider consultation, taking into consideration all risks,
including differences in rates of unintentional iron inges-
tion by young children in populations practicing select-
ive versus universal iron supplementation to infants.
Conclusions
Maternal anaemia is a common and clinically important
problem however the results of this review indicate
Parker et al. BMC Pregnancy and Childbirth 2012, 12:56 Page 9 of 10
http://www.biomedcentral.com/1471-2393/12/56many gaps in the evidence. Such evidence gaps include
the management of anaemia in the postnatal period,
screening for anaemia, and optimal interventions for
treatment. Research priorities include developing stan-
dardised approaches to reporting of laboratory out-
comes, and information on clinical outcomes relevant to
the experiences of pregnant women.
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